-
Je něco špatně v tomto záznamu ?
Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients
M. Grundmann, B. Koristkova, H. Brozmanova, I. Kacirova,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- antikonvulziva terapeutické užití MeSH
- dospělí MeSH
- fenytoin terapeutické užití MeSH
- fruktosa analogy a deriváty terapeutické užití MeSH
- karbamazepin terapeutické užití MeSH
- klonazepam terapeutické užití MeSH
- kombinovaná farmakoterapie metody MeSH
- kyselina valproová terapeutické užití MeSH
- lékové interakce fyziologie MeSH
- lidé MeSH
- monitorování léčiv metody MeSH
- piracetam analogy a deriváty terapeutické užití MeSH
- triaziny terapeutické užití MeSH
- záchvaty farmakoterapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The aim was to study the impact of therapeutic drug monitoring (TDM) on patients on lamotrigine (LTG) therapy and the evaluation of possible drug interactions, especially in triple antiepileptic drug combinations. METHODS: During the period of 2001-2014, 3118 predose samples were taken from 1137 patients >15 years of age as part of their routine TDM. Drug interactions were evaluated using calculation of LTG clearance (CL). RESULTS: Valproic acid (VPA) decreased LTG CL by 66% in bitherapy, and by 35% and 31% in triple therapy with carbamazepine (CBZ) and phenytoin (PHT), respectively. CBZ and PHT increased LTG CL by 52% and 96% in respective bitherapies but by 88% in triple therapy. Clonazepam, levetiracetam, and topiramate had no effect. The LTG therapeutic range (TR) was exceeded in 1% of cases in monotherapy, and in 4%-5% of cases in combination therapy. Only 54% of results were within the TR during 2001-2005, whereas 60%-62% were within the TR during 2006-2014. Adverse drug reactions (ADRs) were reported in 88 cases and occurred more frequently during TR during 2001-2005. Higher number of supratherapeutic levels in combination therapy led to a 3-fold higher incidence of ADR and poorer seizure control, as seizures occurred more often monthly (2.5%) or a few per year (41%) and fewer patients were seizure free (18%). Seizures occurred more often daily and monthly during the first period and in patients with 3 or 4 drugs in combination. CONCLUSIONS: A significantly higher number of supratherapeutic levels were found in combinations with VPA, despite lower doses of LTG. Hepatic enzyme inducers, such as CBZ and PHT only partially compensated for the inhibitory effect of VPA. Decrease of both the frequency of seizures and the incidence of ADRs after TDM implementation suggests that TDM may have given clinicians the opportunity to achieve more optimal patient treatment.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024866
- 003
- CZ-PrNML
- 005
- 20180719091739.0
- 007
- ta
- 008
- 180709s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/FTD.0000000000000433 $2 doi
- 035 __
- $a (PubMed)28682924
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Grundmann, Milan $u *Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; and Departments of †Clinical Pharmacology and ‡Laboratory Diagnostics, University Hospital Ostrava, Ostrava, Czech Republic.
- 245 10
- $a Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients / $c M. Grundmann, B. Koristkova, H. Brozmanova, I. Kacirova,
- 520 9_
- $a BACKGROUND: The aim was to study the impact of therapeutic drug monitoring (TDM) on patients on lamotrigine (LTG) therapy and the evaluation of possible drug interactions, especially in triple antiepileptic drug combinations. METHODS: During the period of 2001-2014, 3118 predose samples were taken from 1137 patients >15 years of age as part of their routine TDM. Drug interactions were evaluated using calculation of LTG clearance (CL). RESULTS: Valproic acid (VPA) decreased LTG CL by 66% in bitherapy, and by 35% and 31% in triple therapy with carbamazepine (CBZ) and phenytoin (PHT), respectively. CBZ and PHT increased LTG CL by 52% and 96% in respective bitherapies but by 88% in triple therapy. Clonazepam, levetiracetam, and topiramate had no effect. The LTG therapeutic range (TR) was exceeded in 1% of cases in monotherapy, and in 4%-5% of cases in combination therapy. Only 54% of results were within the TR during 2001-2005, whereas 60%-62% were within the TR during 2006-2014. Adverse drug reactions (ADRs) were reported in 88 cases and occurred more frequently during TR during 2001-2005. Higher number of supratherapeutic levels in combination therapy led to a 3-fold higher incidence of ADR and poorer seizure control, as seizures occurred more often monthly (2.5%) or a few per year (41%) and fewer patients were seizure free (18%). Seizures occurred more often daily and monthly during the first period and in patients with 3 or 4 drugs in combination. CONCLUSIONS: A significantly higher number of supratherapeutic levels were found in combinations with VPA, despite lower doses of LTG. Hepatic enzyme inducers, such as CBZ and PHT only partially compensated for the inhibitory effect of VPA. Decrease of both the frequency of seizures and the incidence of ADRs after TDM implementation suggests that TDM may have given clinicians the opportunity to achieve more optimal patient treatment.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antikonvulziva $x terapeutické užití $7 D000927
- 650 _2
- $a karbamazepin $x terapeutické užití $7 D002220
- 650 _2
- $a klonazepam $x terapeutické užití $7 D002998
- 650 _2
- $a lékové interakce $x fyziologie $7 D004347
- 650 _2
- $a monitorování léčiv $x metody $7 D016903
- 650 _2
- $a kombinovaná farmakoterapie $x metody $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fruktosa $x analogy a deriváty $x terapeutické užití $7 D005632
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a fenytoin $x terapeutické užití $7 D010672
- 650 _2
- $a piracetam $x analogy a deriváty $x terapeutické užití $7 D010889
- 650 _2
- $a záchvaty $x farmakoterapie $7 D012640
- 650 _2
- $a triaziny $x terapeutické užití $7 D014227
- 650 _2
- $a kyselina valproová $x terapeutické užití $7 D014635
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Koristkova, Blanka
- 700 1_
- $a Brozmanova, Hana
- 700 1_
- $a Kacirova, Ivana
- 773 0_
- $w MED00004503 $t Therapeutic drug monitoring $x 1536-3694 $g Roč. 39, č. 5 (2017), s. 543-549
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28682924 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180719092040 $b ABA008
- 999 __
- $a ok $b bmc $g 1316997 $s 1021787
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 39 $c 5 $d 543-549 $i 1536-3694 $m Therapeutic drug monitoring $n Ther Drug Monit $x MED00004503
- LZP __
- $a Pubmed-20180709